CancerDrs

Colorectal Cancer clinical trials in North Carolina

42 actively recruiting colorectal cancer trials at 31 sites across North Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in North Carolina:
  • Cone Health MedCenter Asheboro — Asheboro, North Carolina
  • Cone Health Cancer Center at Alamance Regional — Burlington, North Carolina
  • Cone Health Cancer Center — Greensboro, North Carolina
  • Cone Health Cancer Center at Drawbridge Parkway — Greensboro, North Carolina
  • Margaret R Pardee Memorial Hospital — Hendersonville, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Sites in North Carolina:
  • University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Sponsor: Incyte Corporation
NCT ID: NCT07284849
Sites in North Carolina:
  • Messino Cancer Center — Asheville, North Carolina
  • The University of North Carolina At Chapel Hill — Chapel Hill, North Carolina
  • Oncology Specialists of Charlotte — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
  • Duke Cancer Center Raleigh — Raleigh, North Carolina
  • Wake Forest University Health Sciences — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…

Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in North Carolina:
  • GSK Investigational Site — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in North Carolina:
  • Local Institution - 0290 — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in North Carolina:
  • WakeMed Raleigh Campus ( Site 0094) — Raleigh, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…

Sponsor: AbbVie
NCT ID: NCT07525206
Sites in North Carolina:
  • Duke University Medical Center /ID# 279322 — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in North Carolina:
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Atrium Health Cabarrus/LCI-Concord — Concord, North Carolina
  • East Carolina University — Greenville, North Carolina
  • Wake Forest University Health Sciences — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in North Carolina:
  • Local Institution - 2144 — Goldsboro, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in North Carolina:
  • Duke University — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in North Carolina:
  • Duke University School of Medicine — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in North Carolina:
  • Duke Cancer Center Durham — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combin…

Sponsor: AbbVie
NCT ID: NCT06820463
Sites in North Carolina:
  • University of North Carolina Medical Center /ID# 267786 — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after the…

Sponsor: NSABP Foundation Inc
NCT ID: NCT07058012
Sites in North Carolina:
  • First Health of the Carolinas — Pinehurst, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uv…

Sponsor: IDEAYA Biosciences
NCT ID: NCT03947385
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Pa…

Sponsor: Phanes Therapeutics
NCT ID: NCT05482893
Sites in North Carolina:
  • Duke Cancer Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…

Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in North Carolina:
  • University of North Carolina — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable …

Sponsor: Kahr Bio Australia Pty Ltd
NCT ID: NCT07235293
Sites in North Carolina:
  • Duke University Medical Center - Duke Cancer Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of DM002 in Patients With Advanced Solid Tumors

The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling…

Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
NCT ID: NCT06751329
Sites in North Carolina:
  • Carolina BioOncology Institute, LLC — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker…

Sponsor: Hoffmann-La Roche
NCT ID: NCT04929223
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…

Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

Sponsor: AstraZeneca
NCT ID: NCT05877599
Sites in North Carolina:
  • Research Site — Charlotte, North Carolina
  • Research Site — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligib…

Sponsor: EvolveImmune United, Inc
NCT ID: NCT07217171
Sites in North Carolina:
  • Duke University Medical Center - Duke Cancer Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, a…

Sponsor: Vividion Therapeutics, Inc.
NCT ID: NCT06004245
Sites in North Carolina:
  • Duke University — Durham, North Carolina
View on ClinicalTrials.gov →

Showing 25 of 42 trials with sites in North Carolina. See all colorectal cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01